Literature DB >> 6419891

Multiplication of hepatitis B virus in fulminant hepatitis B.

C Brechot, J Bernuau, V Thiers, F Dubois, A Goudeau, B Rueff, P Tiollais, J P Benhamou.   

Abstract

The presence in serum of hepatitis B e antigen (HBeAg) and hepatitis B virus DNA, which are each regarded as reflecting multiplication of hepatitis B virus, were looked for one to five days after the onset of hepatic encephalopathy in 64 patients with fulminant hepatitis B. HBeAg and hepatitis B virus DNA were found in the serum of only 24 (37%) and six (9%) patients, respectively. Hepatitis B virus DNA was absent from the serum in all 13 patients positive for anti-HBs. These findings indicate that replication of hepatitis B virus stopped after the onset of hepatic encephalopathy in most of the patients and support the view that an enhanced immune response stops the replication. Agents that inhibit viral multiplication would probably not have any effect at this stage of the disease.

Entities:  

Mesh：

Substances：

Year:  1984        PMID： 6419891      PMCID： PMC1444072          DOI： 10.1136/bmj.288.6413.270

Source DB:  PubMed          Journal:  Br Med J (Clin Res Ed)        ISSN： 0267-0623


  10 in total

1.  e antigen and anti-e in the serum of asymptomatic carrier mothers as indicators of positive and negative transmission of hepatitis B virus to their infants.

Authors:  K Okada; I Kamiyama; M Inomata; M Imai; Y Miyakawa
Journal:  N Engl J Med       Date:  1976-04-01       Impact factor: 91.245

2.  Detection of hepatitis B virus DNA in serum by a simple spot hybridization technique: comparison with results for other viral markers.

Authors:  J Scotto; M Hadchouel; C Hery; J Yvart; P Tiollais; C Brechot
Journal:  Hepatology       Date:  1983 May-Jun       Impact factor: 17.425

3.  Relationship between HBV-specific DNA polymerase and HBe antigen/antibody system in chronic HBV infection: factors determining selection of patients and outcome of antiviral therapy.

Authors:  A Craxi; I V Weller; M F Bassendine; M J Fowler; J Monjardino; H C Thomas; S Sherlock
Journal:  Gut       Date:  1983-02       Impact factor: 23.059

4.  Fulminant hepatic failure.

Authors:  P D Berk; H Popper
Journal:  Am J Gastroenterol       Date:  1978-03       Impact factor: 10.864

5.  Transvenous liver biopsy: an experience based on 1000 hepatic tissue samplings with this procedure.

Authors:  D Lebrec; G Goldfarb; C Degott; B Rueff; J P Benhamou
Journal:  Gastroenterology       Date:  1982-08       Impact factor: 22.682

6.  Hepatitis B antigen (HBSAg) and/or antibodies (anti-HBS and anti-HBC) in fulminant hepatitis: pathogenic and prognostic significance.

Authors:  C G Trepo; D Robert; J Motin; D Trepo; M Sepetjian; A M Prince
Journal:  Gut       Date:  1976-01       Impact factor: 23.059

7.  Type B hepatitis: the infectivity of blood positive for e antigen and DNA polymerase after accidental needlestick exposure.

Authors:  H J Alter; L B Seeff; P M Kaplan; V J McAuliffe; E C Wright; J L Gerin; R H Purcell; P V Holland; H J Zimmerman
Journal:  N Engl J Med       Date:  1976-10-21       Impact factor: 91.245

8.  Enhanced HBsAb production in pathogenesis of fulminant viral hepatitis type B.

Authors:  I L Woolf; N El Sheikh; H Cullens; W M Lee; A L Eddleston; R Williams; A J Zuckerman
Journal:  Br Med J       Date:  1976-09-18

9.  The detection of HBV-DNA in serum by molecular hybridisation: a more sensitive method for the detection of complete HBV particles.

Authors:  I V Weller; M J Fowler; J Monjardino; H C Thomas
Journal:  J Med Virol       Date:  1982       Impact factor: 2.327

10.  Hepatitis B virus DNA in the sera of HBsAg carriers: a marker of active hepatitis B virus replication in the liver.

Authors:  F Bonino; B Hoyer; J Nelson; R Engle; G Verme; J Gerin
Journal:  Hepatology       Date:  1981 Sep-Oct       Impact factor: 17.425
  10 in total
  12 in total

1.  Persistence of HCV replication in non-A, non-B fulminant viral hepatitis.

Authors:  M Yoshiba; K Sekiyama; F Sugata; H Okamoto; M Mayumi
Journal:  Gastroenterol Jpn       Date:  1991-04

2.  Role of humoral immunity against hepatitis B virus core antigen in the pathogenesis of acute liver failure.

Authors:  Zhaochun Chen; Giacomo Diaz; Teresa Pollicino; Huaying Zhao; Ronald E Engle; Peter Schuck; Chen-Hsiang Shen; Fausto Zamboni; Zhifeng Long; Juraj Kabat; Davide De Battista; Kevin W Bock; Ian N Moore; Kurt Wollenberg; Cinque Soto; Sugantha Govindarajan; Peter D Kwong; David E Kleiner; Robert H Purcell; Patrizia Farci
Journal:  Proc Natl Acad Sci U S A       Date:  2018-11-12       Impact factor: 11.205

Review 3.  Acute hepatic failure: limitations of medical treatment and indications for liver transplantation.

Authors:  M Peters; K H Meyer zum Büschenfelde; G Gerken
Journal:  Clin Investig       Date:  1993-11

4.  Recurrent fulminant hepatic failure in an HB carrier after intensive chemotherapy.

Authors:  M Yoshiba; K Sekiyama; S Iwabuchi; M Takatori; Y Tanaka; T Uchikoshi; H Okamoto; K Inoue; F Sugata
Journal:  Dig Dis Sci       Date:  1993-09       Impact factor: 3.199

5.  Significance of anti-pre-S antibodies in patients with fulminant hepatic failure.

Authors:  M Irshad; B M Gandhi; S K Acharya; Y K Joshi; B N Tandon
Journal:  Gastroenterol Jpn       Date:  1990-08

6.  Initial load of hepatitis B virus (HBV), its changing profile, and precore/core promoter mutations correlate with the severity and outcome of acute HBV infection.

Authors:  Shigehiko Sainokami; Koichi Abe; Akihiro Sato; Ryujin Endo; Yasuhiro Takikawa; Kazuyuki Suzuki; Hiroaki Okamoto
Journal:  J Gastroenterol       Date:  2007-03-30       Impact factor: 7.527

7.  What factors determine the severity of hepatitis A-related acute liver failure?

Authors:  V Ajmera; G Xia; G Vaughan; J C Forbi; L M Ganova-Raeva; Y Khudyakov; C K Opio; R Taylor; R Restrepo; S Munoz; R J Fontana; W M Lee
Journal:  J Viral Hepat       Date:  2010-12-08       Impact factor: 3.728

8.  Failure to incriminate hepatitis B, hepatitis C, and hepatitis E viruses in the aetiology of fulminant non-A non-B hepatitis.

Authors:  D Mutimer; J Shaw; J Neuberger; S Skidmore; B Martin; S Hubscher; P McMaster; E Elias
Journal:  Gut       Date:  1995-03       Impact factor: 23.059

9.  Interferon and cyclosporin A in the treatment of fulminant viral hepatitis.

Authors:  M Yoshiba; K Sekiyama; K Inoue; R Fujita
Journal:  J Gastroenterol       Date:  1995-02       Impact factor: 7.527

Review 10.  Intensive liver care and management of acute hepatic failure.

Authors:  R Williams; A E Gimson
Journal:  Dig Dis Sci       Date:  1991-06       Impact factor: 3.199
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.